http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
비소세포성 폐암에서 Gefitinib과 삼칠충초정을 병용 투약하여 약물 내성이 연장된 1례
고명현 ( Myung-hyun Ko ),반경태 ( Gyung-tae Ban ),박소정 ( So-jung Park ),박지혜 ( Ji-hye Park ),이연월 ( Yeon-weol Lee ),조정효 ( Jung-hyo Cho ),유화승 ( Hwa-seung Yoo ) 대전대학교 한의학연구소 2021 혜화의학회지 Vol.30 No.2
Objective : The purpose of this study was to report the case of prolonged drug resistance non-small cell lung cancer (NSCLC) with Samchilchoongcho-Jung (HAD-B1) in combining with Gefitinib. Methods : The patient was diagnosed with Epidermal Growth Factor Receptor mutation (EGFR) NSCLC adenocarcinoma. The patient being treated with Gefitinib was treated with HAD-B1 for prolonged drug resistance. The clinical outcomes were measured by Response Evaluation Criteria in Solid Tumors (RECIST), National Cancer Institute Common Terminology Criteria for Adverse Event (NCI -CTCAE), laboratory findings, etc. Results : After combining treatment, the drug resistance of Gefitinib was prolonged about 20 months. The tumor marker levels were also maintained. NCI-CTCAE 6.0 showed no adverse events. Conclusion: This case study suggested that HAD-B1 may prolong the drug resistance of Gefitinib.
사람의 유방암 세포주인 MDA MB-231 세포에서 CpG 메칠화에 의한 Disabled-2유전자의 발현억제
고명현,오유미,박준호,전병훈,한동민,김원신,Ko Myung Hyun,Oh Yu Mi,Park Jun Ho,Jeon Byung Hoon,Han Dong Min,Kim Won Sin 한국생명과학회 2005 생명과학회지 Vol.15 No.5
사람의 Disabled-2 (Dab2)는 정상세포에서 c-Fos의 발현을 억제하여 세포 성장을 조절하는 암억제 유전자로 추정되어 지고 있다. 많은 암세포에서 Dab2는 유방과 난소의 정상세포에서는 발현이 되지만, 약 $85\%$의 유방과 난소의 종양세포에서는 발현이 줄어들거나, 발현이 억제되는 것으로 알려져 있다. 본 연구에서는 bisulfite 반응에 의한 염기서열 분석법과 MSP방법 등을 이용하여 유방암 세포주인 MDA MB-231세포에서 Dab2 유전자의 promoter상에 존재하는 Cpg island의 methylation된 상태를 분석하였다. 그 결과, 사람의 정상 자궁내막세포에서는 Dab2 promoter 부위가 완전하게 methylation되어 있지 않았다. 그러나 MDA MB-231세포에서는 TATA box 근처 의 CpG dinucleotide에서 비정상적으로 methylation되어 있었다. 이런 비정상적인 CpG dinucleotide의 methylation은 MDA MB-231세포를 5-azacytidine으로 처리하였을 때 methylation이 풀리고, Dab2의 발현이 회복되는 것으로 나타났다. 따라서 인간 유방암 세포주인 MBA MB-231세포에서 Dab2의 발현억제는 Dab2 유전자의 promoter부위의 CpG island의 비정상적인 methylation과 관련이 있는 것으로 여겨진다. Human Disabled-2 (Dab2) is a candidate tumor suppressor gone that regulates cell growth by c-Fos suppression in normal cells. In many cancer cells, Dab2 expression is lost or greatly diminished in $\∼85\%$ of the breast and ovarian cancers. In this study, we have examined the methylation status of CpG island on Dab2 gene promoter using bisulfite-assisted genomic sequencing and methylation specific PCR (MSP) method in human breast cancer cell line, MDA MB-231 cells. In normal human uterus endometrial cells, Dab2 was completely unmethylated. In contrast, Dab2 was methylated on CpG dinucleotides near the TATA_ box in MDA MB-231 cells. following MDA MB-231 cells by treatment with 5-azacytidine, Dab2 gene were demethylated and reexpressed. Result of this study suggested that silencing of Dab2 gene is correlated to CpG island methylation in human breast cancer cell line, MBA MD-231 cells.
알렉티닙과 삼칠충초정을 병용하여 호전된 진행성 비소세포성 폐암환자 1례
고명현,명지수,박소정,전형준,이연월,조종관,유화승,Ko, Myung-hyun,Myong, Ji-soo,Park, So-jung,Jeon, Hyung-joon,Lee, Yeon-weol,Cho, Chong-kwan,Yoo, Hwa-seung 대한암한의학회 2019 大韓癌韓醫學會誌 Vol.24 No.1
Objective: The purpose of this study is to report the clinical effectiveness of advanced non-small cell lung cancer (NSCLC) with Samchilchoongcho-Jung (HAD-B1) in conjunction with Alectinib. Methods: The patient was diagnosed with Anaplastic lymphoma kinase (ALK) mutated (2+) non-small cell lung cancer adenocarcinoma stage IV, suffering from edema of lower extremities, dyspnea, pleural effusion, general weakness, insomnia. The patient being treated with Alectinib was treated with Samchilchoongcho-Jung (HAD-B1) for disease control and symptom management. The clinical outcomes were measured by National Cancer Institute Common Terminology Criteria for Adverse Event (NCI-CTCAE), Numeral rating scale (NRS) and Eastern Cooperative Oncology Group (ECOG). Results: After treatment, dyspnea and edema of lower extremities was relieved from NRS 7 to 5, and 6 to 1 respectively. And ECOG score of the patient was improved from grade 3 to 2. During and after treatment, we didn't find any severe toxicities on laboratory findings. Conclusion: This case study suggests that Samchilchoongcho-Jung (HAD-B1) may improve symptom relief and life quality of NSCLC patient in conjunction with Alectinib.
SRRS를 이용한 측두하악장애 재발환자의 생활 변화에 관한 연구
노곤현,안용우,고명연,Noh, Kon-Hyun,Ahn, Yong-Woo,Ko, Myung-Yun 대한안면통증구강내과학회 2007 Journal of Oral Medicine and Pain Vol.32 No.1
The life changes of TMJ patients were evaluated through the Social Readjustment Rating Scale (SRRS) questionnaire. 33 recurred TMD patients and 32 new TMD patients were studied at the TMJ clinics, Department of Oral Medicine, PNUH from September 2005 to August 2006. The obtained results were as follows: 1. The life change unit(LCU) totals in the recurred TMD patients were significantly higher than those in the control subjects, during the $7{\sim}12$ months before presentation for the hospital. 2. The life change unit(LCU) totals in the recurred TMD patients were higher a little than those in the control subjects during a year before presentation for the hospital. 3. There was no significant difference in LCU totals and life events between the recurred TMD patients and the control subjects by age. 4. There was no significant difference in LCU totals and life events between the married group and unmarried group in the subjects.
오현묵,김슬기,박찬란,고명현,박소정,조종관,박지혜,유화승,이남헌,손창규,조정효,Oh, Hyeon-muk,Kim, Sul-ki,Park, Chan-ran,Ko, Myung-hyun,Park, So-jung,Cho, Chong-kwan,Park, Ji-hye,Yoo, Hwa-seung,Lee, Nam-hun,Son, Chang-gue,Cho, Jung-hyo The Society of Internal Korean Medicine 2021 大韓韓方內科學會誌 Vol.42 No.4
목적: 본 연구는 대전대학교 부속 한방병원에서 암을 주소로 입원치료를 받은 환자를 대상으로 내원 동기 및 만족도를 평가하고자 한다. 방법: 총 100명의 입원환자를 대상으로 의료서비스 만족도 측정을 위한 설문조사를 실시하였다. 통계분석은 독립표본 T검정(Independent t-test), 분산 분석(ANOVA)을 사용하였다. 결과: 암환자들이 한방병원에 내원한 주된 동기는 '암의 전이 및 재발을 예방하기 위해서'로 조사되었다. 환자들은 한방 치료 중 침과 뜸에 대해 가장 높은 만족도를 보였다. 5점 척도로 구성된 만족도 조사에서 한의사 서비스와 관련된 만족도는 평균 4.80점, 의료서비스 이용 관련 만족도는 4.68점으로 나타났다. 결론: 대부분의 암환자는 한방병원의 의료서비스에 만족하는 것으로 나타났고 성별, 연령 및 직업에 따른 한방 의료서비스 만족도에는 유의한 차이가 없었다. Objectives: This study aimed to evaluate the degree of satisfaction of cancer patients and to understand their motives for visiting Korean Medicine Hospital in order to increase satisfaction with Korean medicine among cancer patients. Methods: Data collection was conducted in the form of a survey of 100 inpatients who responded to a self-report questionnaire. Independent t-test and analysis of variance (ANOVA) were used for data analysis. Results: The main reason for visiting Korean Medicine Hospital was to prevent metastasis or recurrence of cancer. Patients showed the highest satisfaction with acupuncture and moxibustion. The average degree of satisfaction related to the doctor service was, on a 5-point scale, 4.80, and that of using procedure was 4.68. Conclusion: Most of the cancer patients are satisfied with the medical services in Korean Medicine Hospital. There were no significant differences in satisfaction degree by gender, age, or occupation.